

Olympus Corporation

Company Presentation

April 2025 Ver. 1

Disclaimer:

- Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes or results.
- Under no circumstances shall Olympus or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.
- Some of the products and/or technology shown herein are future technology concepts that are under development and are not presently available in all countries, including not being available in the United States. There is no time period established as to when or if these products and/or technologies will be available in such markets, including the United States. The safety and effectiveness of these products and technologies and/or the use of these products and technologies have not yet been established in the United States market.

A couple stands on a grassy mountain ridge, looking out over a vast, hazy landscape of rolling hills and mountains under a bright blue sky filled with fluffy white clouds. The couple is seen from behind, silhouetted against the bright sky. The woman has blonde hair tied back, and the man is wearing a dark jacket. The foreground is covered in dry, golden-brown grass.

OLYMPUS

True to Life

"True to Life" is our global brand message that expresses Olympus's commitment to Our Purpose.

At Olympus, we believe everyone should have the opportunity to live life to the full. Every day we are advancing medical technology solutions to help people everywhere fulfill their desires, their curiosity, their dreams, their ambitions, and their lives.



01 As a Globally Leading MedTech Company

02 Our Business Field

03 Company Strategy

04 For a Sustainable Society

05 Fostering a Healthy Organization

06 Company Information

07 Appendix: Olympus History



01

**As a Globally Leading MedTech
company**

A photograph of a woman with long brown hair hugging a young child from behind. The woman is smiling and looking towards the child. The child is wearing a dark, quilted jacket. The background is a blurred outdoor setting with trees and a body of water. The entire image has a blue color overlay.

“

We will continue to make
people's lives **healthier, safer,
and more fulfilling.**

”

Corporate Philosophy

OUR PURPOSE

Making people's lives healthier, safer and more fulfilling

OUR CORE VALUES



PATIENT FOCUS

We put patients at the heart of everything.



INTEGRITY

We do the right thing.



INNOVATION

We look for new ways to make things better.



IMPACT

We take accountability and get things done.



EMPATHY

We care for one another and work together.

Our Contribution to Patients Care

1.9 million


**New Incidents of
Colon Cancer**

Source : GLOBOCAN 2022
<https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>

48 million

**Colonoscopies Performed
Worldwide**

*Numbers of US, Canada, Poland, South Korea, Australia, India, and Russia (as of 2022); Japan, Germany, France, Italy, Spain, and UK (as of 2021) ; China (as of 2019)



Our Contribution to Patients Care



100

Diseases or Conditions Treated

At Olympus we have versatile medical devices with the ability to treat approximately 100* diseases or conditions

Source: Based on the Company's research, as of April 2024




TOP 3


Cancers Treated

Olympus provides products/solutions for lung, colorectum and stomach
- Three cancers from the top 5* highest incidence of cancers

*Top 3 highest incidence of cancers excluding breast and prostate cancer
Source: GLOBOCAN 2022
<https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>



Making people's lives healthier, safer and more fulfilling



28,838

Employees Worldwide*

* As of March 2024

37

Countries or Regions*

* As of March 2024

Making people’s lives healthier, safer and more fulfilling



TOP 100

Global Innovator

Since 2012 to 2020, and in 2022 and 2023, Olympus has been awarded as one of the top 100 most innovative companies in the world.

<https://clarivate.com/top-100-innovators/>



294

Awards

Since 1966, Olympus has been consistently honored with national and international design awards for its innovative product designs*

*As of March 2024



15,000

Patents

across our product portfolio*

*As of March 2024



CO2 “0”

Emissions by FY2031


We set as a target of achieving net zero CO2 emissions by FY2031 from our site operations



02

Our Business Field

Revenue by Business Divisions




Revenue by Region




¥936.2bn


March 2024 *Approx.




¥121.5bn




¥351.3bn




¥242.8bn



¥106.3bn






¥88.1bn



¥26.1bn

Revenue and Operating Profit



Note) We split off the imaging business to a special purpose company established by Japan Industrial Partners, Inc. on January 1, 2021. In this regard, imaging division is categorized as a discontinued operation, effective Q2 of FY2021 and figures of FY2020 is restated.
*Due to rounding, the total may not add up to 100%

Gastrointestinal Solutions Division

Gastrointestinal Endoscopy System



Video endoscopy system




Ultrasound system


GI Endotherapy



CRC devices



HPB devices



Hemostasis

Endoscopic Solutions Ecosystem (Digital Healthcare Solutions)



Intelligent ecosystem operating software platform



AI insights and computer-aided detection/diagnosis

Reprocessing



Endoscope reprocessor



Chemicals, accessories, and peripherals

Medical Services



Repair center

Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.

Surgical and Interventional Solutions Division


Respiratory



Bronchoscopy Systems



Bronchoscopic Devices



Lung Cancer



COPD
(Chronic Obstructive Pulmonary Disease)


Urology



Visualization



Stone Management



BPH
(Benign Prostatic Hyperplasia)



BPH + Bladder Cancer

Surgical (Surgical Endoscopy, Surgical Devices, Ear, Nose, and Throat)



Surgical Endoscopy Systems



Advanced Energy Devices



Surgical Microscope



Integrated Procedure Room Solutions



Rhino-laryngoscopy Systems

Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.



03

Company Strategy

Guiding Principles

Patient safety and sustainability



- 1 Resolve pending commitments to the FDA, build a foundation of trust through measurable actions and data with regulatory bodies and with our customers.
- 2 Lead in organization health and ESG

Innovation for growth



- 3 Strengthen the Olympus® brand; elevate the experience of our customers
- 4 Grow our business through purposeful innovation and acquisitions


Productivity



- 5 Build a high performing organization focused on patient safety and product quality
- 6 Support simplicity and operational efficiency

“ Making people’s lives healthier, safer, and more fulfilling. ”

Olympus aims to grow by focusing on three therapeutic areas



We **target three therapeutic areas** which are a strategic fit with our mission to **elevate the standard of care**, for which we can provide **differentiated value through our core capabilities**, and for which there is **growing demand**.

FY2025 transition: Strong rebound based on value pools

BUSINESS AND GLOBAL EXPANSION



- 1 Expected Growth momentum across GI portfolio in North America
- 2 Positive Feedback about EVIS X1™ Endoscopy System
- 3 Growth opportunities in emerging markets

CARE PATHWAY ENHANCEMENT



- 4 Regulatory clearance of our first single-use ureteroscope

INTELLIGENT ENDOSCOPY ECOSYSTEM



- 5 Successful roadshow, first releases planned in Europe for 2H of FY2025

STRATEGIC M&A



Activities to enable investments and innovation




QARA – functional transformation globally

- Execute transformation with the aim of a **single global quality system** and fully harmonize processes
- **Enhance Global Quality and Compliance functions** to support consistent execution
- Resolve compliance issues and **complete remediation**




R&D – investments to accelerate innovation

- Apply an **unmet need-oriented innovation** approach
- Invest for future by furthering an **innovation engine**
- Pro-actively seek out **strategic partnerships**
- **Work to accelerate time-to-market**



Mfg & SCM – opportunity for COGS improvements

- Improve **efficiency and cost** to apply a fit-for-purpose organization and processes
- Actions include **site and resource streamlining, fast-track efficiencies, procurement and supply chain** best-practices, and uncover benefits from digitization




Global TOM* – efficiencies by an improved operations

- Further fine-tune our **global governance and operation** to establish a high-performing organization of a global medical company that **unlocks capital to drive innovation**
- Enable **cross-functional and effective decision-making, with efficient resource allocation** and rigorous execution to fund & deliver key projects *TOM = target operating model

Support patient safety according to the highest industry standards

FY24-26 Financials

Competitive growth along with steady value creation




*constant currency basis **Adjusted for extraordinary Items
- Exclude "Other income / expenses" - No adjustment will be made for the impact of exchange rate fluctuations; actual exchange rate will be used

04

For a Sustainable Society



Common Topics in ESG*



Environment

- Climate Change / Carbon Neutrality
- Circular Economy
- GHG Emissions
- Water & waste management



Social

- Human Rights
- Diversity, equality and inclusion
- Workplace safety
- Healthcare Access & Outcome



Governance

- Corporate Risk Management
- Management Structure
- Board Structure and Diversity
- Reporting Transparency

*Major examples only / not limited

ESG six focus areas and materiality topics for contributing to solutions to social issues



Healthcare Access and Outcome

Contribution to health equity and access



Compliance, Product Quality and Safety

Quality and safety in product, service and solution



Responsible Supply Chain

Supply chain risk mitigation and resilience




Healthy Organization

Diversity, equity and inclusion



Carbon Neutral Society and Circular Economy

Circularity through product stewardship, carbon emissions (Scope 1, 2 and 3)



Corporate Governance

Corporate governance and reporting transparency

Focus Area 1 : Healthcare Access and Outcome



Olympus recognizes the healthcare business as a domain conducive to our efforts in contributing to society by exercising our prowess in the areas in which we most excel. We will aim to contribute to society by delivering innovative products that facilitate improved healthcare outcomes and training opportunities for HCPs.

Materiality Topics

- Top Priority**
- Contribution to health equity and access
 - Contribution to health equity
 - HCP training and enablement
 - Strategy to improve accessibility to product

KPI

CRC* related training in target emerging countries and regions:

+20%

CRC* related online/hybrid training provided with HCPs globally:

+20%

*CRC: Colorectal cancer

- High Priority**
- Innovation to improve healthcare outcomes
 - Public awareness building on early detection and treatment

- Others**
- Corporate citizenship and philanthropy

Contribution to SDGs



Focus Area 2 : Compliance, Product Quality and Safety



As a company providing medical devices, Olympus' foremost priority should be the safety of patients. We are endeavoring to observe anti-corruption and other compliance measures and our accordance with the laws and regulations of respective countries to prioritize the quality and safety of our products.

Materiality Topics

Top Priority ■ Quality and safety in product, service, and solution

KPI

Timely ESG disclosures according to SASB* Standards

*SASB: Sustainability Accounting Standards Board

High Priority ■ Business ethics and compliance
■ Privacy, information, and cyber security

Others ■ Tax transparency
■ Ethical marketing practice
■ Risks and crisis management, and risk culture
■ Innovation to improve manufacturing process

Contribution to SDGs



Focus Area 3 : Responsible Supply Chain



Materiality Topics

Top Priority ■ Supply chain risk mitigation and resilience

KPI

Annual assessment/monitoring for multi-tier supply chain risks

High Priority ■ Human rights commitment in supply chain management

Contribution to SDGs



The stable provision of medical devices is indispensable to provide stable availability of healthcare in society. In addition to fulfilling our responsibility to deliver a stable supply of our products, we will actively work together with our suppliers to address social issues, such as those involving the environment and human rights.

Focus Area 4 : Healthy Organization



Olympus defines a healthy organizational culture as one in which each and every employee can perform at their best, and is engaged in a variety of initiatives towards its aim of becoming such an organization.

Materiality Topics

Top Priority

- Diversity, equity, and inclusion

KPI

Management positions held by women

Eligible male employees in Japan* taking parental leave

by FY2026 : **100%** *Olympus Corporation

High Priority

- Employee development and engagement
- Workplace safety and human rights

Contribution to SDGs



Focus Area 5 : Carbon Neutral Society and Circular Economy



Olympus recognizes climate change as a serious issue that endangers the integrity of the global environment, as well as being an issue which affects our business activities. We will continue to promote a variety of ongoing initiatives toward the achievement of carbon neutrality into the future.

Materiality Topics

Top Priority

- Scope 1 and 2 carbon emissions
- Scope 3 emissions
- Circularity through product stewardship

KPI

Net-zero:

Net-zero GHG emissions across Scope 1, 2, and 3 by FY2040

Carbon Neutral:

In our site operations across Scope 1 and 2 by FY2031

High Priority

- Water and waste management
- Climate risk resilience

Others

- Environmental reporting transparency

Contribution to SDGs



Focus Area 6 : Corporate Governance



Olympus has, over the course of many years, focused on strengthening our corporate governance so that we remain a company that is trusted by our stakeholders. We recognize that doing so is of vital importance for the sustainability of our company and will continue to strive to enhance corporate governance into the future.

Materiality Topics

Top Priority ■ Corporate governance and reporting transparency

KPI

Enterprise Risk Management:
Applied consistently across the globe

Others ■ Involvement of other stakeholders

Contribution to SDGs





05

Fostering a Healthy Organization

Employee Engagement and Enablement Survey

2021	Core Values Survey <ul style="list-style-type: none">▪ Follow-up measures: Taking action in each region to improve the issues identified from the survey
2022	Core Values Interim Survey <ul style="list-style-type: none">▪ Received FDA warning letters▪ Launched remediation and quality transformation program Elevate
2024	Our Core Values refresh <ul style="list-style-type: none">▪ Conduct initiatives to activate new core values
First Half of 2025	Core Values Survey <ul style="list-style-type: none">▪ This survey will be adjusted to the refreshed core values.

Olympus has taken and tracked measures from the last Core Values Survey, an employee engagement and enablement survey conducted in 2021.

Company-wide initiatives have since included site visits by Executive Officers, optimization of decision-making processes, visualization and follow-up of the current status of employee work-life balance, and enhancement and optimization of global working guidelines.

In November 2022, we conducted a Core Values Survey Check-in to review the status of our organization and reinforced and adjusted activities to improve our culture and employee experience.

Olympus is currently working on establishing a long-term regular cadence of employee listening. The next measure planned is a Core Values Survey in the first half of 2025.

Our Development and Learning Offers Support Professional Growth and Global Collaboration

	Olympus Purpose, Values, Culture	Personal and Professional Growth	Functional / Job Based Skill Building
Leaders		<ul style="list-style-type: none">▪ Leadership Programs▪ 360 Feedback for Leaders	<ul style="list-style-type: none">▪ Product and Sales Trainings
Individuals	<ul style="list-style-type: none">▪ Onboarding Sessions▪ Our Core Values Activation▪ DEI Training	<ul style="list-style-type: none">▪ Business Skills▪ Language Courses▪ Cross-cultural Collaboration Workshops	<ul style="list-style-type: none">▪ Trainings for Employees in Manufacturing and Repair
Teams		<ul style="list-style-type: none">▪ Career Workshops	<ul style="list-style-type: none">▪ Marketing Academy

Olympus provides a wide range of development offers, both on a global and regional/local level, directed at leaders, individual contributors, and teams.

In addition, we focus on learning with and from each other to build our professional and personal skills.

06

Company Information



Company Outline

Company Name	Olympus Corporation
Market	Tokyo Stock Exchange, Prime Market (7733)
Established	October 12, 1919
Head Office	2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan
Share Capital	124.643 billion yen (As of March 31, 2024)
Consolidated Revenue	936.2 billion yen (Fiscal year ended March 31, 2024)
Consolidated Headcount	28,838 (As of March 31, 2024)



Executive Officers



Yasuo Takeuchi

Director, Representative Executive Officer, Executive Chairperson, President and Chief Executive Officer, and ESG Officer



John de Csepel

Executive Officer and Chief Medical Officer



Frank Drewalowski

Executive Officer and Gastrointestinal Solutions



Tatsuya Izumi

Executive Officer and Chief Financial Officer



Gabriela Kaynor

Executive Officer and Chief Strategy Officer



Tetsuo Kobayashi

Executive Officer and Chief Manufacturing and Supply Officer



Seiji Kuramoto

Executive Officer and Surgical and Interventional Solutions



Syed Naveed

Executive Officer and Chief Technology Officer



Shigeto Ohtsuki

Executive Officer and Chief Human Resources Officer



Boris Shkolnik


Executive Officer and Chief Quality Officer



Neil Boyden Tanner

Executive Officer and Global General Counsel

Olympus Locations



As of January 2024



07

Appendix: Olympus History

Olympus History



Sales launch of **Asahi** microscope.

1920



Launch of **Showa GK** immersion microscope.

1927



Renaming of company to **Olympus Optical Co., Ltd.**

1949



Launch of the **GT-I** gastrocamera.

1952



1919

Founding of **Olympus** by Takeshi Yamashita under the company name **Takachiho Seisakusho**; established in Tokyo, Japan, for domestic production of microscopes.



1921

Registration of **Olympus name** as a trademark.



1936

Launch of first Olympus camera, the **Semi-Olympus I**, after development of Zuiko photographic lenses.

1950

Development of world's **first practical** gastrocamera.



1959

Launch of **Olympus PEN**, an innovative half-frame film camera.

Olympus History



Launch of **GTF™** gastrocamera with fiberscope.

1964



Establishment of **Olympus Corporation of America** as a sales subsidiary for microscopes and medical equipment in the United States.

1968



Launch of **OM-1**, a compact, lightweight, SLR camera, which was initially named M-1.

1972



Establishment of **Olympus Camera Corporation** as a sales base in the United States.

1977



1964

Start up of **Olympus Optical Co.** in Hamburg, Germany, as Olympus' European headquarters.



1966

Launch of **GFS** gastrofiberscope, which didn't have a camera mechanism on the tip.



1969

Introduction of **ZUIKO PEARLCORDER™** recorder, the world's first microcassette tape recorder.




1975

Collaboration with Winter & Ibe GmbH to produce surgical rigid medical endoscopes, with Olympus supplying the optical systems.

1979

Opening of the **National Service Center** in San Jose, California, for U.S.-based Olympus equipment repairs.

Olympus History



Olympus History

Launch of **BX** series of biological microscopes and **UIS** series of object lenses, which improved product appeal in the AX, BX, CX, and IX series of microscopes.

1993



Launch of **C-800L/D-300L** and **C-400L/D-200L**, Olympus' first consumer digital cameras.

1996



Launch of **MX50** semiconductor inspection microscope.

1996



Introduction of **IPLEX™** industrial videoscope system.

2001



1995

Establishment of **Olympus Endo-Repair Europa GmbH**, endoscope repair service center for the European market, in Hamburg, Germany.



1996

Launch of **FLUOVIEW™** confocal laser scanning biological microscope.



2000

Introduction of **EVIS EXERA™** series endoscopic video system.



2002

Launch of **VISERA™** series, an integrated video system for surgery.

Olympus History



Launch of
electrosurgical
Itknife™
device.

2002



Launch of **E-1** digital SLR
camera with
interchangeable lenses.

2003



Renaming of
company to
Olympus
Corporation.

2003



Launch of **LEXT™**
OLS3000 microscope, the first
in the LEXT 3D confocal laser
microscope series.

2004

Launch of **FLUOVIEW™**
FV1000 system, the world's first
laser scanning microscope
with two independent scanners.

2004



Acquisition of **R/D Tech
Inc.** to expand the
nondestructive testing
device business.

2005



Opening of Shirakawa
Medical Equipment Service
Operation Center (SORC
Shirakawa) in Japan.

2005



Olympus History

Launch of **EVIS EXERA II™** and **EVIS LUCERA SPECTRUM** endoscopic video systems.

2006



Merger with **Gyrus PLC** to deliver additional technology and sales/marketing knowhow to the Olympus surgical business.

2008



Launch of **EPOCH1000** series ultrasonic flaw detectors.

2009



Launch of **BX3** system biological microscope.

2010



Acquisition of **Innov-X Systems, Inc.** to expand Olympus' presence in nondestructive testing.

2010



2006

Opening of Shanghai Medical Equipment Service Operation Center (SORC Shanghai) in China.



2008

Establishment of **Olympus Vietnam Co., Ltd.** manufacturing facility for cameras and medical equipment.



2009


Launch of **Olympus PEN E-P1** mirrorless camera.




2010

Formation of **OSTE**, Olympus Surgical Technologies Europe.

Olympus History



Olympus History



*Not Available for Sale in the United States

OLYMPUS

A thick, yellow, horizontal swoosh underline that is slightly wider in the center, positioned directly beneath the word OLYMPUS.

Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates.